FTSE 100 preview: Muted start ahead of Fed Chair testimony

FTSE 100 preview: Muted start ahead of Fed Chair testimony
Written by:
Tsveta van Son
10th July 2019
Updated: 11th March 2020

The FTSE 100 looks set to open little changed this morning, with investors awaiting the testimony of Federal Reserve Chair Jerome Powell which will be eyed for clues on the US central bank’s monetary policy. In company news Barratt Developments (LON:BDEV) has posted a trading update this morning.

FTSE 100 seen flat

Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today.

IG’s opening calls suggest that Britain’s blue-chip index will start trading 0.05 percent higher at 7,540 points. In the US, shares fell last night ahead of Powell’s testimony.

“While by no means a done deal, our base is still that the Fed will cut rates pre-emptively in July,” said Mark Haefele, global chief investment officer at UBS Global Wealth Management, as quoted by CNBC. “However, even after Friday’s reaction to the strong jobs data, markets are pricing close to 1% of rate reductions by the end of next year. We think markets have gone too far in pricing lower rates.” Asian shares meanwhile have climbed higher this morning.

In the UK, the Footsie closed little changed in the previous session, giving up 12.80 points to end trading 0.17 percent lower at 7,536.47, with investors staying on the sidelines ahead of this week’s Fed Chair comments. Ocado (LON:OCDO) was the session’s biggest riser in percentage terms despite posting a wider interim loss.

Wednesday’s releases

This Wednesday’s macroeconomic releases include the UK’s gross domestic product (GDP) for May, due out at 09:30 BST. IG reports that growth is expected to come in at 1.4 percent in May, from 1.3 percent. Minutes from the Fed’s latest policy meeting are scheduled to be released at 19:00 BST, after the London market closes.

On the corporate front, Barratt Developments has posted a trading update, while GlaxoSmithKline (LON:GSK) has unveiled the results from a study evaluating a prospecting HIV treatment.

Invezz uses cookies to provide you with a great user experience. By using Invezz, you accept our privacy policy.